Iris Pharma of France, an ophthalmic preclinical and clinical CRO, and RxGen, a Connecticut-based specialty preclinical CRO focused on the development and application of translational research models, have formed a strategic alliance to offer fully integrated “bench-to-bedside” ophthalmology research services.

Iris Pharma can offer immediate access to RxGen’s nonhuman primate ophthalmic research models and related preclinical in vivo services, via a flexible engagement model.

“The ability to offer integrated packages of services and a comprehensive and seamless program of preclinical and clinical drug development will improve our competitive position in the marketplace and generate significant value for our clients,” said Yann Quentric, head of business development and marketing at Iris Pharma.

“Effectively translating discovery to approved therapeutics demands time and cost-efficient program design and management, capitalizing on the best available preclinical test systems while maintaining a clear eye on the clinical pathway,” said Matthew Lawrence, CEO of RxGen.